Sanofi Expands Immunology Leadership with Dren Bio’s DR-0201 Acquisition

Sanofi has announced the acquisition of DR-0201, a targeted bispecific myeloid cell engager developed by Dren Bio, Inc., marking a significant step forward in autoimmune disease treatment. DR-0201, a CD20-directed bispecific antibody, has shown promising B-cell depletion in pre-clinical and early clinical studies, potentially offering long-term, treatment-free remission for patients with refractory B-cell mediated autoimmune diseases like lupus. This acquisition reinforces Sanofi’s commitment to pioneering immunology breakthroughs by leveraging the power of deep B-cell depletion to reset the adaptive immune system.

Dren Bio’s CEO, Nenad Tomasevic, expressed confidence in Sanofi’s ability to unlock the full potential of DR-0201, ensuring that this cutting-edge treatment reaches patients in need. Meanwhile, Houman Ashrafian, Sanofi’s Head of R&D, emphasized that this move aligns with Sanofi’s ambition to become a leader in immunology, bringing life-changing therapies to those who have exhausted traditional treatment options. With this strategic acquisition, Sanofi is poised to reshape the future of autoimmune care, offering hope to millions battling complex immune disorders.